This report will provide a brief summary of what we, at the CRA, have been up to thanks primarily to our committed members and the support of our partners and friends.
Additional Reports
2024-2025 Annual Report
2023-2024 Annual Report
2022-2023 Annual Report
2021-2022 Annual Report
2020-2021 Annual Report
2019-2020 Annual Report
2018-2019 Annual Report
2017-2018 Annual Report
Related Resources
View All
Clinical Guidelines
CRA living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs
This Canadian Rheumatology Association (CRA) guideline provides contemporary recommendations for the pharmacological management of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drug (DMARD) therapy. Recommendations are developed using the GRADE approach with a multidisciplinary panel composed of rheumatologists, researchers, methodologists, and […]
April 23, 2026
Clinical Guidelines
Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Guideline for the Management of Axial Spondyloarthritis
The management of axial spondyloarthritis (axSpA) is a complex and rapidly changing field for Canadian rheumatologists. The Spondyloarthritis Research Consortium of Canada (SPARCC) and the Canadian Rheumatology Association (CRA) last updated treatment recommendations for the management of axSpA in 2014(1,2). […]
April 22, 2026
Clinical Guidelines
CRA/CanRIO guidelines for the management of baseline immunosuppression in individuals with pre-existing rheumatic diseases initiating immune checkpoint inhibitors
This living guideline offers up-to-date guidance on the management of baseline immunosuppression (IS) for pre-existing rheumatic diseases (PRDs) when initiating cancer immunotherapy with immune checkpoint inhibitors (ICIs). Split into 2 parts, this guideline provides contemporary baseline IS recommendations for individuals […]
September 1, 2025